Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04393792
Other study ID # SPON-AK-0420
Secondary ID 2020-001721-31
Status Recruiting
Phase Phase 1
First received
Last updated
Start date May 5, 2020
Est. completion date March 2022

Study information

Verified date September 2021
Source Hampshire Hospitals NHS Foundation Trust
Contact Afroze Khan, MBBS MRCS
Phone +447885903693
Email Afroze.Khan@nhs.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

COVID-19 is highly infectious and transmission of the virus is thought to be similar to that of influenza which can be transferred through droplets released when a person coughs, sneezes or talks. Studies have shown that nasal rinsing and mouth washes may be an important way to deliver treatments that could reduce the amount of a virus that is present in the nose and mouth. This also could mean that there is less virus available to pass on to others. We want to see if the use of nose rinses and mouth washes using Povidone-Iodine will reduce the the amount of virus in the nose and throat of people who have tested positive for COVID-19 disease and also reduce the spread of infection within their household.


Description:

COVID-19 is highly infectious and transmission of the virus is thought to be similar to that of influenza which can be transferred through droplets released when a person coughs, sneezes or talks. Studies have shown that nasal rinsing and mouth washes may be an important way to deliver treatments that could reduce the amount of a virus that reaches other parts of the body. This also could mean that there is less virus available to pass on to others. We want to see if the use of nasal rinsing and mouth washes will reduce the spread of infection within your household by reducing and removing the virus from your mouth and nose. Once the participants have been recruited they will be randomly allocated to one of two groups. Each arm will have the same number of participants. The two arms will be : 1. nose rinse and mouthwash with Isotonic saline alone. This will be the control arm. 2. nose rinse and mouthwash with Povidone-Iodine taken 3 times a days for three days. Before treatment begins, each participant will have one pre-treatment swab of the back of the nose and the back of the throat taken. Once allocated each participant will be asked to have 4 further swabs of the mouth and nose taken on days 2,4,7 & 14. Participants will be patients and healthcare staff who have tested positive for COVID-19. Healthcare staff who are self isolating will also asked their co-residents/family members at home to take the treatment and provide swabs in the same manner. Participants who are patients and are admitted to hospital will be well enough to perform the nasal rinses and mouth washes as treatments and provide the same swabs. All participants will be provided with informational videos on how to do the treatments and how to take the swabs. Participants who are not healthcare staff will have swabs taken as part of the local drive through testing service. All participants will be asked to download a free smartphone app (Umotif) to upload information about daily symptoms and whether they have provided swabs on the required days. The swabs will be tested for the amount of virus in the labs at Hampshire Hospitals NHS Foundation Trust and analysed to determine if the treatment arm of Povidone-Iodine is reducing the amount of virus compared to the isotonic saline arm. All results will be anonymised prior to analysis. The study team will know the participants' study-specific data; no personal data about participants will be used without their explicit consent and only for the purposes of protocol adherence and data to answer the study question. Once the last swab has been taken and delivered to the laboratory, the trial will have ended for that participant. Results of the swabs will be part of the study data and collated in readiness for analysis by the study statistician. The results will be made available for peer-reviewed publication and presentation at conferences.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date March 2022
Est. primary completion date March 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Healthcare worker OR patient on a general ward who has had a positive COVID-19 test OR a person who is co-residing with an affected staff member or patient who is now at home in self-isolation. - capable of giving informed consent - able to self-administer the sinus rinses and mouth washes - able to have healthcare professional-led swabs OR self-administer the oral and nasopharyngeal swabs - aged 18 years and over. Exclusion Criteria: - not capable of giving informed consent - unable to self-administer the sinus rinses and mouth washes - unable to have healthcare professional-led swabs OR self-administer the oral, nasal and/OR nasopharyngeal swabs - unable to send swabs to the study team via the approved methods described in participant information leaflet and protocol - under 18 years of age. - known hypersensitivity to Iodine - at risk of aspiration due to an unsafe swallow - hyperthyroidism or other manifest thyroid diseases - herpetiform dermatitis (Duhring's disease) - planned or undergoing radioiodine treatment - actively Breastfeeding - pregnant

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Povidone-Iodine
0.23% three times daily (tds) for 3 days
Normal saline
0.9% three times daily (tds) for 3 days

Locations

Country Name City State
United Kingdom Hampshire Hospitals NHS Foundation Trust Basingstoke Hampshire

Sponsors (1)

Lead Sponsor Collaborator
Hampshire Hospitals NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in viral load in the oral and nasopharyngeal cavity viral load as measured by real time polymerase chain reaction (PCR) Day 0, 2, 3, 7, 14
Secondary Symptom severity in primary participants and co-residents Visual analogue score 1-5 per symptom via a smartphone app Days 0 to 14
See also
  Status Clinical Trial Phase
Completed NCT04369456 - Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients N/A
Completed NCT04527471 - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 Phase 2
Recruiting NCT04410510 - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 Phase 2/Phase 3
Withdrawn NCT04383899 - Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019
Completed NCT04542915 - COVID-19-Related Health and Practices Among Dental Hygienists
Not yet recruiting NCT04400019 - Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) Phase 2/Phase 3
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Completed NCT04532632 - Taste and Smell Impairment in Critically Ill COVID-19 Patients
Terminated NCT04954014 - Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients Phase 2
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Completed NCT04413435 - Clinical Characteristics of Critically Ill Patients With COVID-19
Terminated NCT05593770 - International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response Phase 2/Phase 3
Completed NCT04510493 - Canakinumab in Patients With COVID-19 and Type 2 Diabetes Phase 3
Active, not recruiting NCT04587219 - The Study of "Gam-COVID-Vac" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older Phase 2
Withdrawn NCT05430958 - Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers Phase 1
Completed NCT04596579 - SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida
Completed NCT04405934 - COG-UK Project Hospital-Onset COVID-19 Infections Study N/A
Enrolling by invitation NCT04484025 - SPI-1005 Treatment in Moderate COVID-19 Patients Phase 2
Terminated NCT04442230 - NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) Phase 2
Terminated NCT04642638 - Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure Phase 2/Phase 3